Skip to main content
Premium Trial:

Request an Annual Quote

Spotfire Recruits Ladd to Lead New Work Group

Premium

CAMBRIDGE, Mass.--Spotfire has recruited William Ladd as director of bioinformatics to lead its new Bioinformatics Rapid-Application-Development group, an interdisciplinary team of computer science, biology, chemistry, and statistics specialists based here. The group will work with pharmaceutical and biotech customers to develop technical decision support systems based on Spotfire's core product offerings. Solutions will target areas such as gene expression and clinical trials analysis, high-throughput screening, combinatorial chemistry, and pharmacogenomics. As evidence that this approach can be successful, the company pointed to its collaboration with DuPont Pharmaceuticals, which resulted in the launch of Spotfire Leads Discoverer, a system for managing and sharing screening and chemical structure information over the web. Before joining Spotfire, Ladd had been director of bioinformatics methods at Gene Logic, and, prior to that, spent over five years at Merck where he developed research applications for the company's discovery system.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.